scholarly journals A Review on Nanosuspensionspromising Drug Delivery Strategy.

2012 ◽  
Vol 3 (1) ◽  
pp. 764-776 ◽  
Author(s):  
Toshi Chaurasia . ◽  
Divya Singh . ◽  
Nimisha . ◽  
Dipti Srivastava .
2020 ◽  
Author(s):  
Ellaine Salvador ◽  
Almuth F. Kessler ◽  
Julia Hörmann ◽  
Malgorzata Burek ◽  
Catherine T. Brami ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e108880 ◽  
Author(s):  
Hong Chen ◽  
Cherry C. Chen ◽  
Camilo Acosta ◽  
Shih-Ying Wu ◽  
Tao Sun ◽  
...  

2017 ◽  
Vol 53 (62) ◽  
pp. 8735-8738 ◽  
Author(s):  
Heeren M. Gordhan ◽  
Jillian E. Milanes ◽  
Yijian Qiu ◽  
Jennifer E. Golden ◽  
Kenneth A. Christensen ◽  
...  

A new drug delivery strategy was investigated for the development of potent anti-parasitic compounds againstTrypanosoma brucei, the causative agent of African sleeping sickness.


2016 ◽  
Vol 3 (3) ◽  
pp. 209-220 ◽  
Author(s):  
Maria T. P. Albuquerque ◽  
Juliana Y. Nagata ◽  
Anibal R. Diogenes ◽  
Asma A. Azabi ◽  
Richard L. Gregory ◽  
...  

2005 ◽  
Vol 21 (7) ◽  
pp. 299-301 ◽  
Author(s):  
Giancarlo A. Biagini ◽  
Stephen A. Ward ◽  
Patrick G. Bray

2020 ◽  
Author(s):  
Victoria Yan ◽  
Kristine Yang ◽  
Elliot Ballato ◽  
Kenisha Arthur ◽  
Dimitra Georgiou ◽  
...  

Glycolysis inhibition remains aspirational in cancer therapy. We recently described a promising phosphonate inhibitor of Enolase for cancers harboring deletions in ENO1. Here, we describe the application of nitroheterocycle pro-drugs capitalizing on tumor hypoxia. These bioreducible pro-drugs exhibit up to 14-fold greater potency under hypoxic conditions compared to normoxia and exhibit robust stability in biological fluids. Our work provides strong proof-of-concept for using bioreduction as a pro-drug delivery strategy in the context of Enolase inhibition.


Sign in / Sign up

Export Citation Format

Share Document